BioTime Receives Authorization To Begin Pivotal Human Clinical Trial Of Renevia In Europe

Reneviaa to be utilized in the treatment of HIV-related lipoatrophy, a disorder estimated to afflict more than 3.5 million patients globally Patient enrollment initiated; expected to be completed in 2015 ALAMEDA, Calif.-- --BioTime, Inc. today reported that it has received authorization to begin its pivotal human clinical trial of Reneviaa in Europe. In the trial, Renevia will be used in combination with the patient's own fat-derived cells and injected into portions of the patient's face where there has been a loss of fat from under the skin .

http://ift.tt/1x4gDLO